Observational studyAmerican journal of respiratory and critical care medicine2026
Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults.
Observational study in American journal of respiratory and critical care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does Tuberculosis Leave a Thromboinflammatory Memory After Cure? A Narrative Review with a Conceptual Framework on Hypercoagulability, Cellular Reservoirs, and Extracellular Vesicle Signaling.International journal of molecular sciences · 2026Review
- The ghost of tuberculosis past.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
rationalePost-tuberculosis lung disease (PTLD), which includes restrictive and obstructive patterns of impairment, develops in 50% or more of survivors of tuberculosis (TB), yet mechanisms and associated risk factors are poorly understood.
objectivesWe sought to identify clinical and transcriptomic risk factors for PTLD phenotypes.
methodsIn a prospective, observational, cohort study, we enrolled adults (month 0) with newly diagnosed pulmonary TB in Nairobi, Kenya, and evaluated clinical and transcriptomic risk factors for PTLD. Participants completed 6 months of standard anti-TB therapy. PTLD was defined as abnormal spirometry at month 12 (ie, 6 months posttreatment) with either a restrictive or obstructive pattern. MEASUREMENTS AND MAIN
resultsWe enrolled 205 participants, of whom 103 (50.2%) had PTLD, including 60 with restrictive PTLD and 43 obstructive PTLD. Participants with PTLD had lower mid-upper arm circumference (MUAC) and cough peak flow. In multivariable analyses, having more lung quadrants involved on radiograph at diagnosis was a risk factor for both restrictive PTLD (adjusted odds ratio [aOR], 2.1; P <.001) and obstructive PTLD (aOR, 2.2; P <.001). Prior TB was associated with obstructive PTLD (aOR, 5.4; P <.001). Gene expression improved clinical predictive models. In transcriptomic analyses, restrictive PTLD was associated with upregulation of IL-6/JAK/STAT3 and TNF-α signaling at diagnosis (false discovery rate [FDR] <0.2). In contrast, obstructive PTLD was associated with transcriptomic upregulation of IFN-α and IFN-γ signaling responses (FDR <0.2) at month 6.
conclusionsDespite common clinical risk factors (lower MUAC, radiographic lung involvement), PTLD phenotypes have unique transcriptional signatures. Restrictive PTLD is marked by early profibrotic inflammation. In contrast, obstructive PTLD is characterized by persistent inflammation at treatment completion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.